RS54911B1 - Lečenje neurodegenerativnih oboljenja porfirinom - Google Patents

Lečenje neurodegenerativnih oboljenja porfirinom

Info

Publication number
RS54911B1
RS54911B1 RS20160388A RSP20160388A RS54911B1 RS 54911 B1 RS54911 B1 RS 54911B1 RS 20160388 A RS20160388 A RS 20160388A RS P20160388 A RSP20160388 A RS P20160388A RS 54911 B1 RS54911 B1 RS 54911B1
Authority
RS
Serbia
Prior art keywords
neurodegenerative diseases
porphyrin
treatment
porphyrin treatment
neurodegenerative
Prior art date
Application number
RS20160388A
Other languages
English (en)
Inventor
Manisha Patel
Brian Day
John Mcmanus
Original Assignee
Aeolus Sciences Inc
Nat Jewish Health
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeolus Sciences Inc, Nat Jewish Health, Univ Colorado Regents filed Critical Aeolus Sciences Inc
Publication of RS54911B1 publication Critical patent/RS54911B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Jedinjenje koje ima formulu:naznačeno time, što je M metal.Prijava sadrži još 9 patentnih zahteva.
RS20160388A 2010-10-06 2011-10-06 Lečenje neurodegenerativnih oboljenja porfirinom RS54911B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39027010P 2010-10-06 2010-10-06
EP11831640.5A EP2625180B1 (en) 2010-10-06 2011-10-06 Porphyrin treatment of neurodegenerative diseases
PCT/US2011/055172 WO2012048164A2 (en) 2010-10-06 2011-10-06 Porphyrin treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
RS54911B1 true RS54911B1 (sr) 2016-10-31

Family

ID=45928446

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160388A RS54911B1 (sr) 2010-10-06 2011-10-06 Lečenje neurodegenerativnih oboljenja porfirinom

Country Status (19)

Country Link
US (1) US20130225545A1 (sr)
EP (1) EP2625180B1 (sr)
JP (1) JP5908485B2 (sr)
KR (1) KR101932149B1 (sr)
AU (1) AU2011311903B2 (sr)
CA (1) CA2813570A1 (sr)
DK (1) DK2625180T3 (sr)
ES (1) ES2574789T3 (sr)
HR (1) HRP20160514T1 (sr)
HU (1) HUE029083T2 (sr)
IL (1) IL225624A (sr)
LT (1) LT2625180T (sr)
NZ (1) NZ609924A (sr)
PL (1) PL2625180T3 (sr)
PT (1) PT2625180E (sr)
RS (1) RS54911B1 (sr)
SI (1) SI2625180T1 (sr)
SM (1) SMT201600196B (sr)
WO (1) WO2012048164A2 (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2785339A4 (en) 2011-12-02 2015-11-25 Univ Colorado Regents NEUROLOGICAL TREATMENTS WITH METALLOPORPHYRIN
WO2016168343A1 (en) * 2015-04-13 2016-10-20 National Jewish Health Thiocyanate salts for anti-inflammation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571908A (en) * 1987-01-02 1996-11-05 Sun Company, Inc. (R&M) Porphyrins
DE69813898T2 (de) * 1997-11-03 2004-03-11 Duke University Substituierte porphyrinen
AU771259B2 (en) * 1998-04-24 2004-03-18 Aeolus Sciences, Inc. Substituted porphyrins
WO2000009111A2 (en) * 1998-08-11 2000-02-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibitors of amyloid formation
MXPA01007451A (es) * 1999-01-25 2004-03-10 Nat Jewish Med & Res Center Porfirinas sustituidas.
WO2003006426A1 (en) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Aromatic guanylhydrazones as effective compounds against neurodiseases
JP2006527196A (ja) * 2003-06-06 2006-11-30 ユーカリオン，インコーポレイテッド 経口で生体利用可能な低分子量メタロポルフィリン
GB0415663D0 (en) * 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound
JP2009298731A (ja) * 2008-06-13 2009-12-24 Tokyo Metropolitan Univ 酸化傷害を抑制する金属ポルフィリン錯体、及びそれを用いた医薬組成物
EP2473171A4 (en) * 2009-09-02 2012-07-11 Univ Colorado Regents METHODS OF TREATING MITOCHONDRIAL DISORDERS USING METALLOPORPHYRINS

Also Published As

Publication number Publication date
DK2625180T3 (en) 2016-06-06
ES2574789T3 (es) 2016-06-22
KR20130115275A (ko) 2013-10-21
PT2625180E (pt) 2016-06-07
HRP20160514T1 (hr) 2016-09-23
SI2625180T1 (sl) 2016-08-31
AU2011311903B2 (en) 2016-11-17
NZ609924A (en) 2015-02-27
US20130225545A1 (en) 2013-08-29
WO2012048164A2 (en) 2012-04-12
WO2012048164A3 (en) 2012-07-19
CA2813570A1 (en) 2012-04-12
EP2625180A2 (en) 2013-08-14
PL2625180T3 (pl) 2016-10-31
EP2625180A4 (en) 2014-05-14
JP5908485B2 (ja) 2016-05-11
EP2625180B1 (en) 2016-03-02
SMT201600196B (it) 2016-08-31
KR101932149B1 (ko) 2018-12-26
HUE029083T2 (en) 2017-02-28
IL225624A (en) 2017-11-30
JP2013542936A (ja) 2013-11-28
LT2625180T (lt) 2016-09-12
IL225624A0 (en) 2013-06-27
AU2011311903A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
UA110338C2 (en) Chemical compounds
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
RS54730B1 (sr) Inhibitori beta sekretaze
RS54207B1 (sr) Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja
CR20130045A (es) Compuestos terapéuticos
PH12015502546A1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
RS54386B1 (sr) Antiviralna jedinjenja
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
MX2015002040A (es) Baricitinib deuterado.
EA201591122A1 (ru) Гетероциклическое соединение
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201590296A1 (ru) Дейтерированный ибрутиниб
CR20130539A (es) Triazolopiridinas
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
EA201690911A1 (ru) Соединения диметилбензойной кислоты
MX2015012629A (es) Compuestos de imidazo piridina.
RS54488B1 (sr) Kristalni konjugat naloksol-polietilen glikol
EA201690894A1 (ru) Феноксиэтилы
FR2989110B1 (fr) Aube de stator formee par un ensemble de parties d'aube
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
UA107592C2 (uk) Композиція для боротьби з захворюваннями рослин і її застосування
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.